Mytra 15 mg. 30 mg. FC tablets.
PDF Leaflet Revision Date: 27 August 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of major depressive illness.
Dosage (summary)
Initial dose 15 mg, may increase to 45 mg; preferably at bedtime.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- MAO inhibitors
- Alcohol
- Serotonergic agents
Contraindications
- Hypersensitivity
- Pregnancy
- Lactation
- Children under 18
- Concomitant MAOIs
Common side effects
- Drowsiness
- Dizziness
- Increased appetite
- Dry mouth
- Constipation
Counselling Points
- Avoid alcohol
- Monitor for suicidal thoughts
- Gradual withdrawal recommended
Serious warnings
- Suicidal thoughts
- Severe cutaneous adverse reactions
- Bone marrow depression
Important Disclaimer
The Mytra 15 mg. 30 mg. FC tablets. professional information leaflet below is the property of Novagen Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
